Back to Journals » Clinical Epidemiology » Volume 5 » Supplement 1 Comorbidity and Cancer Survival

Comorbidity and survival of Danish prostate cancer patients from 2000–2011: a population-based cohort study

Authors Nguyen-Nielsen M, Nørgaard M, Jacobsen JB, Borre M, Thomsen RW, Søgaard M

Received 1 May 2013

Accepted for publication 6 June 2013

Published 1 November 2013 Volume 2013:5(Supplement 1 Comorbidity and Cancer Survival) Pages 47—55


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Mary Nguyen-Nielsen,1 Mette Nørgaard,1 Jacob Bonde Jacobsen,1 Michael Borre,2 Reimar Wernich Thomsen,1 Mette Søgaard1

1Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; 2Department of Urology, Aarhus University Hospital, Aarhus, Denmark

Objective: We investigated temporal changes in overall survival among prostate cancer (PC) patients and the impact of comorbidity on all-cause mortality.
Methods: We conducted a population-based cohort study in the Central Denmark Region (1.2 million inhabitants). Using medical registries, we identified 7,654 PC patients with first-time PC diagnosis within the period 2000–2011 and their corresponding comorbidities within 10 years prior to the PC diagnosis. We estimated 1- and 5-year survival in four consecutive calendar periods using a hybrid analysis and plotted Kaplan–Meier survival curves. We used Cox proportional hazards regression to compute 1- and 5-year age-adjusted mortality rate ratios (MRRs) for different comorbidity levels. All estimates are reported with their corresponding 95% confidence intervals (CI).
Results: The annual number of PC cases doubled over the 12-year study period. Men aged <70 years accounted for the largest proportional increase (from 33% to 47%). The proportion of patients within each comorbidity category remained constant over time. One-year survival increased from 82% (CI: 80%–84%) in 2000–2002 to 92% (CI: 90%–93%) in 2009–2011, while 5-year survival increased from 43% (CI: 40%–46%) to 65% (CI: 62%–67%) during the same time intervals. Improvements in 5-year survival were most prominent among patients aged <80 years and among those with no comorbidity (from 51% to 73%) and medium comorbidity (from 32% to 54%). Improvements in survival were much smaller for those with high comorbidity (from 33% to 39%). The 1-year age-adjusted MRR for patients with high comorbidity (relative to patients with no comorbidity) increased over time from 1.84 (CI: 1.19–2.84) to 3.67 (CI: 2.49–5.41), while the 5-year age-adjusted MRR increased from 1.73 (CI: 1.34–2.23) to 2.38 (CI: 1.93–2.94).
Conclusion: Overall survival of PC improved substantially during 2000–2011, although primarily among men with low comorbidity. All-cause mortality was highest among PC patients with high comorbidity, and their relative 1- and 5-year mortality increased over time compared to those without comorbidity.

Keywords: prostate cancer, comorbidities, Charlson Index, survival

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.